AKT1 and cancer: While PI3K and AKT remain promising drug targets for selective inhibition/elimination of phenotypically plastic cancer cells, high toxicity and mixed efficacy for many candidate therapeutics in clinical trials indicates a need for further research to better characterize the druggability of this key signaling pathway.